Elisabetta Esposito

List of Publications by Year
in descending order

106 papers	3,400 citations	147566 31 h-index	161609 54 g-index
106 all docs	106 docs citations	106 times ranked	4031 citing authors

#	Article	IF	Citations
1	Lipid Nanostructures for Antioxidant Delivery. Antioxidants, 2022, 11, 238.	2.2	0
2	Antioxidant-containing monoolein aqueous dispersions: a preliminary study. Drug Delivery and Translational Research, 2022, , 1.	3.0	3
3	Natural Polyphenol-Containing Gels against HSV-1 Infection: A Comparative Study. Nanomaterials, 2022, 12, 227.	1.9	4
4	A spectrofluorometric analysis to evaluate transcutaneous biodistribution of fluorescent nanoparticulate gel formulations. European Journal of Histochemistry, 2022, 66, .	0.6	6
5	Ethosomes and Transethosomes as Cutaneous Delivery Systems for Quercetin: A Preliminary Study on Melanoma Cells. Pharmaceutics, 2022, 14, 1038.	2.0	24
6	Design of propolis-loaded film forming systems for topical administration: The effect of acrylic acid derivative polymers. Journal of Molecular Liquids, 2021, 322, 114514.	2.3	17
7	Challenges in the Physical Characterization of Lipid Nanoparticles. Pharmaceutics, 2021, 13, 549.	2.0	44
8	Ethosomes and Transethosomes for Mangiferin Transdermal Delivery. Antioxidants, 2021, 10, 768.	2.2	44
9	Formulative Study and Intracellular Fate Evaluation of Ethosomes and Transethosomes for Vitamin D3 Delivery. International Journal of Molecular Sciences, 2021, 22, 5341.	1.8	25
10	â€œPlurethosomeâ€•as Vesicular System for Cutaneous Administration of Mangiferin: Formulative Study and 3D Skin Tissue Evaluation. Pharmaceutics, 2021, 13, 1124.	2.0	10
11	Lipid-Based Nanosystems as a Tool to Overcome Skin Barrier. International Journal of Molecular Sciences, 2021, 22, 8319.	1.8	53
12	Mangiferin-Loaded Smart Gels for HSV-1 Treatment. Pharmaceutics, 2021, 13, 1323.	2.0	5
13	The Potential of Caffeic Acid Lipid Nanoparticulate Systems for Skin Application: In Vitro Assays to Assess Delivery and Antioxidant Effect. Nanomaterials, 2021, 11, 171.	1.9	26
14	Monolein Aqueous Dispersions as a Tool to Increase Flavonoid Solubility: A Preliminary Study. Proceedings (mdpi), 2021, 78, 25.	0.2	1
15	Gallic acid loaded poloxamer gel as new adjuvant strategy for melanoma: A preliminary study. Colloids and Surfaces B: Biointerfaces, 2020, 185, 110613.	2.5	25
16	Design of Nanosystems for the Delivery of Quorum Sensing Inhibitors: A Preliminary Study. Molecules, 2020, 25, 5655.	1.7	15
17	Design and Characterization of Ethosomes for Transdermal Delivery of Caffeic Acid. Pharmaceutics, 2020, 12, 740.	2.0	46
18	Ethosomes for Coenzyme Q10 Cutaneous Administration: From Design to 3D Skin Tissue Evaluation. Antioxidants, 2020, 9, 485.	2.2	32

#	Article	IF	Citations
19	A Correlative Imaging Study of in vivo and ex vivo Biodistribution of Solid Lipid Nanoparticles . International Journal of Nanomedicine, 2020, Volume 15, 1745-1758.	3.3	14
20	Ellagic Acid Containing Nanostructured Lipid Carriers for Topical Application: A Preliminary Study. Molecules, 2020, 25, 1449.	1.7	29
21	Nanoparticulate Gels for Cutaneous Administration of Caffeic Acid. Nanomaterials, 2020, 10, 961.	1.9	23
22	Nanotechnological Strategies for Administration of Poorly Soluble Neuroactive Drugs. Proceedings (mdpi), 2020, 78, .	0.2	1
23	Nanomedicines to Treat Skin Pathologies with Natural Molecules. Current Pharmaceutical Design, 2019, 25, 2323-2337.	0.9	30
24	Lipid nanostructures for antioxidant delivery: a comparative preformulation study. Beilstein Journal of Nanotechnology, 2019, 10, 1789-1801.	1.5	17
25	Bioactive Molecules from Vegetable Sources for the Treatment of Cutaneous Pathologies and Disorders Part 2. Current Pharmaceutical Design, 2019, 25, 2313-2313.	0.9	0
26	Bioactive Molecules from Vegetable Sources for the Treatment of Cutaneous Pathologies and Disorders Part 1. Current Pharmaceutical Design, 2019, 25, 2207-2207.	0.9	0
27	Lipid Nanoparticles and Active Natural Compounds: A Perfect Combination for Pharmaceutical Applications. Current Medicinal Chemistry, 2019, 26, 4681-4696.	1.2	19
28	New Strategies for the Delivery of Some Natural Anti-oxidants with Therapeutic Properties. Mini-Reviews in Medicinal Chemistry, 2019, 19, 1030-1039.	1.1	11
29	Thermal Magnetic Field Activated Propolis Release From Liquid Crystalline System Based on Magnetic Nanoparticles. AAPS PharmSciTech, 2018, 19, 3258-3271.	1.5	23
30	Monoolein liquid crystalline phases for topical delivery of crocetin. Colloids and Surfaces B: Biointerfaces, 2018, 171, 67-74.	2.5	20
31	Production and Characterization of a Clotrimazole Liposphere Gel for Candidiasis Treatment. Polymers, 2018, 10, 160.	2.0	11
32	Production and Characterization of Nanoparticle Based Hyaluronate Gel Containing Retinyl Palmitate for Wound Healing. Current Drug Delivery, 2018, 15, 1172-1182.	0.8	13
33	Nanostructured lipid carriers (NLC) for the delivery of natural molecules with antimicrobial activity: production, characterisation and in vitro studies. Journal of Microencapsulation, 2017, 34, 63-72.	1.2	38
34	Solid lipid nanoparticles for the delivery of 1,3,5-triaza-7-phosphaadamantane (PTA) platinum (II) carboxylates. Materials Science and Engineering C, 2017, 74, 357-364.	3.8	6
35	Nanoformulations for dimethyl fumarate: Physicochemical characterization and in vitro / in vivo behavior. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 285-296.	2.0	29
36	Monoolein aqueous dispersions as a delivery system for quercetin. Biomedical Microdevices, 2017, 19, 41.	1.4	15

#	Article	IF	Citations
37	Microparticles containing gallic and ellagic acids for the biological control of bacterial diseases of kiwifruit plants. Journal of Plant Diseases and Protection, 2017, 124, 563-575.	1.6	11
38	L-dopa co-drugs in nanostructured lipid carriers: A comparative study. Materials Science and Engineering C, 2017, 72, 168-176.	3.8	20
39	Lipid nanoparticles for administration of poorly water soluble neuroactive drugs. Biomedical Microdevices, 2017, 19, 44.	1.4	22
40	Data on scaling up and in vivo human study of progesterone lipid nanoparticles. Data in Brief, 2017, 14, 639-642.	0.5	2
41	Progesterone lipid nanoparticles: Scaling up and in vivo human study. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 437-446.	2.0	29
42	Nanostructured lipid systems modified with waste material of propolis for wound healing: Design, in vitro and in vivo evaluation. Colloids and Surfaces B: Biointerfaces, 2017, 158, 441-452.	2.5	57
43	Natural antimicrobials in spray-dried microparticles based on cellulose derivatives as potential eco-compatible agrochemicals. Journal of Plant Diseases and Protection, 2017, 124, 269-278.	1.6	12
44	Nanostructured lipid dispersions for topical administration of crocin, a potent antioxidant from saffron (Crocus sativus L.). Materials Science and Engineering C, 2017, 71, 669-677.	3.8	49
45	NafionÂ®-Containing Solid Lipid Nanoparticles as a Tool for Anticancer Pt Delivery: Preliminary Studies. Journal of Chemistry, 2017, 2017, 1-6.	0.9	4
46	Ethosomes and organogels for cutaneous administration of crocin. Biomedical Microdevices, 2016, 18, 108.	1.4	26
47	Encapsulation of cannabinoid drugs in nanostructured lipid carriers. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 102, 87-91.	2.0	39
48	Gelified reverse micellar dispersions as percutaneous formulations. Journal of Drug Delivery Science and Technology, 2016, 32, 270-282.	1.4	3
49	Structural Studies of Lipid-Based Nanosystems for Drug Delivery: X-ray Diffraction (XRD) and Cryogenic Transmission Electron Microscopy (Cryo-TEM). , 2016, , 861-889.		4
50	Cubic Phases, Cubosomes and Ethosomes for Cutaneous Application. Current Pharmaceutical Design, 2016, 22, 5382-5399.	0.9	13
51	Effect of new curcuminâ€containing nanostructured lipid dispersions on human keratinocytes proliferative responses. Experimental Dermatology, 2015, 24, 449-454.	1.4	21
52	Production, Physico-Chemical Characterization and Biodistribution Studies of Lipid Nanoparticles. Journal of Nanomedicine & Nanotechnology, 2015, 06, .	1.1	9
53	Lipid-based nanoparticles containing cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as innovative vehicle for Pt complexes: Production, characterization and in vitro studies. International Journal of Pharmaceutics, 2015, 492, 291-300.	2.6	7
54	Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study. Materials Science and Engineering C, 2015, 48, 328-336.	3.8	43

#	Article	IF	Citations
55	Biodistribution of nanostructured lipid carriers: A tomographic study. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 145-156.	2.0	29
56	Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science and Engineering C, 2015, 48, 294-300.	3.8	11
57	Structural Studies of Lipid-Based Nanosystems for Drug Delivery: X-ray Diffraction (XRD) and Cryogenic Transmission Electron Microscopy (Cryo-TEM). , 2015, , 1-23.		3
58	Polymeric microparticles for fenretinide administration. Macromolecular Symposia, 2014, 345, 14-23.	0.4	0
59	Cationic lipid nanosystems as carriers for nucleic acids. New Biotechnology, 2014, 31, 44-54.	2.4	35
60	Effect of nanostructured lipid vehicles on percutaneous absorption of curcumin. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 121-132.	2.0	41
61	Curcumin containing monoolein aqueous dispersions: A preformulative study. Materials Science and Engineering C, 2013, 33, 4923-4934.	3.8	42
62	Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: A preliminary study as possible vaccine against genital herpes. International Journal of Pharmaceutics, 2013, 440, 229-237.	2.6	31
63	Evaluation of Monooleine Aqueous Dispersions as Tools for Topical Administration of Curcumin: Characterization, In Vitro and Ex-Vivo Studies. Journal of Pharmaceutical Sciences, 2013, 102, 2349-2361.	1.6	42
64	Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies. International Journal of Pharmaceutics, 2013, 454, 695-702.	2.6	70
65	Design and characterization of fenretinide containing organogels. Materials Science and Engineering C, 2013, 33, 383-389.	3.8	14
66	Clotrimazole nanoparticle gel for mucosal administration. Materials Science and Engineering C, 2013, 33, 411-418.	3.8	58
67	Analysis of the Drug Release Profiles from Formulations Based on Micro and Nano Systems. Current Analytical Chemistry, 2013, 9, 37-46.	0.6	4
68	Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 306-314.	2.0	106
69	Analysis of the Drug Release Profiles from Formulations Based on Micro and Nano Systems. Current Analytical Chemistry, 2012, 9, 37-46.	0.6	1
70	Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors. International Journal of Pharmaceutics, 2012, 431, 176-182.	2.6	10
71	Eudragit^{Â®}microparticles for the release of budesonide: A comparative study. Indian Journal of Pharmaceutical Sciences, 2012, 74, 403.	1.0	17
72	Colloidal dispersions for the delivery of acyclovir: A comparative study. Indian Journal of Pharmaceutical Sciences, 2011, 73, 687.	1.0	16

#	Article	IF	Citations
73	Effect of charge and lipid concentration on in-vivo percutaneous absorption of methyl nicotinate from liposomal vesicles. Journal of Pharmacy and Pharmacology, 2010, 57, 1169-1176.	1.2	10
74	Evaluation of Percutaneous Absorption of Naproxen from Different Liposomal Formulations. Journal of Pharmaceutical Sciences, 2010, 99, 2819-2829.	1.6	31
75	Liposomes- and ethosomes-associated distamycins: a comparative study. Journal of Liposome Research, 2010, 20, 277-285.	1.5	26
76	Distamycins: Strategies for Possible Enhancement of Activity and Specificity. Mini-Reviews in Medicinal Chemistry, 2010, 10, 218-231.	1.1	10
77	Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine. Pharmaceutical Research, 2008, 25, 1521-1530.	1.7	164
78	Acyclovir delivery systems. Expert Opinion on Drug Delivery, 2008, 5, 1217-1230.	2.4	27
79	EudragitÂ® microparticles as a possible tool for ophthalmic administration of acyclovir. Journal of Microencapsulation, 2007, 24, 445-456.	1.2	15
80	Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. International Journal of Pharmaceutics, 2007, 339, 52-60.	2.6	26
81	Nanosystems for skin hydration: a comparative study. International Journal of Cosmetic Science, 2007, 29, 39-47.	1.2	24
82	Hyaluronan-based microspheres as tools for drug delivery: a comparative study. International Journal of Pharmaceutics, 2005, 288, 35-49.	2.6	97
83	Cellulose acetate butyrate microcapsules containing dextran ion-exchange resins as self-propelled drug release system. Biomaterials, 2005, 26, 4337-4347.	5.7	57
84	Cubosome Dispersions as Delivery Systems for Percutaneous Administration of Indomethacin. Pharmaceutical Research, 2005, 22, 2163-2173.	1.7	237
85	Production of Lipospheres for Bioactive Compound Delivery. , 2004, , 23-40.		2
86	Cationic Lipospheres as Delivery Systems for Nucleic Acid Molecules. , 2004, , 143-159.		0
87	Ethosomes and liposomes as topical vehicles for azelaic acid: a preformulation study. Journal of Cosmetic Science, 2004, 55, 253-64.	0.1	34
88	Lipid-based supramolecular systems for topical application: A preformulatory study. AAPS PharmSci, 2003, 5, 62-76.	1.3	141
89	Multifunctional microcapsules for pancreatic islet cell entrapment: design, preparation and in vitro characterization. Biomaterials, 2003, 24, 3101-3114.	5.7	29
90	Amphiphilic association systems for Amphotericin B delivery. International Journal of Pharmaceutics, 2003, 260, 249-260.	2.6	20

#	Article	IF	Citations
91	Effect of long-term stabilization of cationic liposomes as defibrotide delivery system for antithrombotic activity. Drug Development Research, 2002, 55, 127-138.	1.4	2
92	Spray dried Eudragit microparticles as encapsulation devices for vitamin C. International Journal of Pharmaceutics, 2002, 242, 329-334.	2.6	90
93	Acrylic microspheres for oral controlled release of the biguanide buformin. International Journal of Pharmaceutics, 2001, 218, 13-25.	2.6	8
94	Pectinâ€Based Microspheres. Annals of the New York Academy of Sciences, 2001, 944, 160-179.	1.8	23
95	Liposomes as carriers for DNAâ€“PNA hybrids. Journal of Controlled Release, 2000, 68, 237-249.	4.8	56
96	Production of Eudragit Microparticles by Spray-Drying Technique: Influence of Experimental Parameters on Morphological and Dimensional Characteristics. Pharmaceutical Development and Technology, 2000, 5, 267-278.	1.1	82
97	In Vitro Antiproliferative Activity of Isothiocyanates and Nitriles Generated by Myrosinase-Mediated Hydrolysis of Glucosinolates from Seeds of Cruciferous Vegetables. Journal of Agricultural and Food Chemistry, 2000, 48, 3572-3575.	2.4	71
98	Dextran cross-linked gelatin microspheres as a drug delivery system. European Journal of Pharmaceutics and Biopharmaceutics, 1999, 47, 153-160.	2.0	66
99	Preparation and characterization of Ca-alginate microspheres by a new emulsification method. International Journal of Pharmaceutics, 1998, 170, 11-21.	2.6	79
100	In VitroCytotoxic Activity of Some Glucosinolate-Derived Products Generated by Myrosinase Hydrolysis. Journal of Agricultural and Food Chemistry, 1996, 44, 1014-1021.	2.4	70
101	Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA. International Journal of Pharmaceutics, 1996, 139, 69-78.	2.6	108
102	Gelatin microspheres: influence of preparation parameters and thermal treatment on chemico-physical and biopharmaceutical properties. Biomaterials, 1996, 17, 2009-2020.	5.7	152
103	Gelatin microspheres as a new approach for the controlled delivery of synthetic oligonucleotides and PCR-generated DNA fragments. International Journal of Pharmaceutics, 1994, 105, 181-186.	2.6	27
104	Liposome-associated retinoids: production, characterization and antiproliferative activity on neoplastic cells. European Journal of Pharmaceutical Sciences, 1994, 2, 281-291.	1.9	13
105	Comparative study on the release kinetics of methyl-nicotinate from topic formulations. International Journal of Pharmaceutics, 1993, 90, 43-50.	2.6	15
106	DNA binding activity and inhibition of DNA-protein interactions. Biochemical Pharmacology, 1992, 44, 1985-1994.	2.0	8